Key result
Vanillic acid pretreatment reduces myocardial infarct size and troponin-I in rat heart failure models.
Why the study?
Vanillic acid is a plant-derived phenolic compound suggested to possess cardioprotective properties, but its effects in experimental heart failure models remained underexplored.
Does oral pretreatment with vanillic acid attenuate myocardial injury, infarct size, oxidative stress, inflammation, and apoptosis in male Wistar rats with isoprenaline-induced heart failure?
Does oral pretreatment with vanillic acid attenuate myocardial injury, infarct size, oxidative stress, inflammation, and apoptosis in male Wistar rats with isoprenaline-induced heart failure?
This preclinical study demonstrates that vanillic acid pretreatment mitigates isoprenaline-induced myocardial necrosis, oxidative stress, inflammation, and apoptosis in rats, supporting further investigation as a potential cardioprotective compound.
Answers are grounded in this paper and cite their sources.
Premature for clinical use in heart failure; leaves open translation of vanillic acid cardioprotection to humans.
BACKGROUND: Heart failure (HF) continues to pose a major health concern worldwide, frequently arising from ongoing myocardial damage driven by oxidative stress, inflammatory processes, and programmed cell death. While synthetic medications are widely used, natural compounds with multi-targeted actions are gaining attention. Vanillic acid (VA), a plant-derived phenolic compound, is suggested to possess cardioprotective properties; yet, its effects in experimental HF models remain underexplored. METHODS: This study evaluated the impact of VA pretreatment on isoprenaline (ISO)-induced HF in male Wistar rats. A total of forty animals were randomly allocated into four distinct groups: sham, VA, ISO, and ISO + VA. ISO was administered subcutaneously to induce cardiac injury, while VA was given orally for 10 days prior to ISO exposure. Biochemical markers of myocardial damage, oxidative stress, inflammatory cytokines, infarct size, and apoptotic gene expression (Bax, Bcl-2) were assessed through ELISA, histological staining, and real-time PCR. RESULTS: ISO administration caused significant elevation in cardiac enzymes (LDH, CK-MB, cTn-I), pro-inflammatory markers (IL-1β, TNF-α), lipid peroxidation (MDA), and Bax expression, along with reduced antioxidant enzyme activity (CAT, SOD, GPx), IL-10, and Bcl-2 levels. VA pretreatment mitigated these alterations, demonstrating a notable decrease in infarct size, oxidative damage, inflammation, and apoptosis. No adverse effects were observed in the VA-only group. CONCLUSION: VA exhibited substantial cardioprotective effects against ISO-induced myocardial injury, likely through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. The results indicate that VA could be a valuable natural adjunct in the management of HF.
No takes yet. Share an insight, caveat, or question.
Khaksarian et al. (2026) studied Isoprenaline-induced heart failure / myocardial injury (n=40). Vanillic acid vs. Normal saline orally for 10 days followed by subcutaneous isoprenaline (100 mg/kg/day) on days 11 and 12 was evaluated on Myocardial infarct size and biochemical markers of cardiac injury (LDH, CK-MB, cTn-I), inflammation, oxidative stress, and apoptosis at day 13 (p=<0.05). Vanillic acid pretreatment (20 mg/kg/day) significantly reduced myocardial infarct size (p<0.05) and cardiac troponin-I (p<0.01) in rats with isoprenaline-induced heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: